Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis. Patients expressing COVID-19 are more susceptible to Mucormycosis (MCR) and thus fall easy prey to decease accounting for this global threat. Their mortality rates range around 32-70% depending on the organs affected and grow even higher despite the treatment. The many contemporary recommendations strongly advise using liposomal amphotericin B and surgery as first-line therapy whenever practicable. MCR is a dangerous infection that requires an antifungal drug administration on appropriate prescription, typically one of the following: Amphotericin B, Posaconazole, or Isavuconazole since the fungi that cause MCR are resistant to other medications like fluconazole, voriconazole, and echinocandins. Amphotericin B and Posaconazole are administered through veins (intravenously), and isavuconazole by mouth (orally). From last several years so many compounds are developed against invasive fungal disease but only few of them are able to induce effective treatment against the micorals. Adjuvant medicines, more particularly, are difficult to assess without prospective randomized controlled investigations, which are challenging to conduct given the lower incidence and higher mortality from Mucormycosis. The present analysis provides insight into pathogenesis, epidemiology, clinical manifestations, underlying fungal virulence, and growth mechanisms. In addition, current therapy for MCR in Post Covid-19 individuals includes conventional and novel nano-based advanced management systems for procuring against deadly fungal infection. The study urges involving nanomedicine to prevent fungal growth at the commencement of infection, delay the progression, and mitigate fatality risk

Unlocking the potential of nanobiohybrids to combat environmental pollution

The destructive effects of the world's population growth, which have led to the overuse of primary resources, are evident today. Recently, the world has hit an 8 billion population mark, which is accompanied by an increase in waste generation. Anthropogenic activities lead to environmental pollution that is a problem of great importance, and it is essential to develop economically sound, eco-friendly, and sustainable technologies to tackle this ever-increasing problem of the 21st century. Innovations are required since they can contribute to the creation of sophisticated, sustainable, and novel goods for ecological repair. Such properties can be seen in the current advancements of nanotechnologies and new performing nanomaterials. They have a substantial surface area, enzymatic activity, and responsiveness and are easily functionalized to chemically modify their characteristics. This chapter examines current advancements in bioremediation methods used in conjunction with various nanocomposites and nanobiohybrids to recover the environment from pollution. Special focus is placed on environmentally friendly and regenerative nanosolutions, as well as their secure properties

Regulatory processes involved in clinical trials and intellectual property rights around vaccine development

This chapter explores the critical intersection of regulatory processes and intellectual property rights (IPR) within the context of vaccine development. With the ongoing global focus on public health and the urgent need for effective vaccines, understanding the intricate regulatory frameworks and IPR landscape becomes vital for stakeholders in the pharmaceutical and biotechnology industries. The chapter begins by providing a comprehensive overview of the regulatory processes governing clinical trials, delving into the various stages, including preclinical testing, investigational new drug applications, and the distinct phases of human clinical trials. The ethical considerations inherent in clinical research and the importance of adherence to regulatory guidelines are emphasized. Moreover, the chapter examines the roles and responsibilities of regulatory bodies involved, such as the Food and Drug Administration in the United States, the European Medicines Agency in Europe, and other regional authorities. Furthermore, this chapter explores the intricate relationship between vaccine development and IPR. It examines the impact of IPR on vaccine accessibility, including potential monopolies, high prices, and implications for global health equity. The protection of intellectual property rights, such as patents, trademarks, and licensing agreements, is discussed in detail. Strategies for balancing IPR protection with the need for affordable and accessible vaccines are explored, including technology transfer, compulsory licensing, and patent pooling. The global regulatory frameworks governing clinical trials are also addressed, focusing on international guidelines, harmonization efforts, and regional challenges. The chapter examines regulatory approval processes, postmarketing surveillance, and expedited pathways for vaccine development, including emergency use authorization. Lastly, the chapter delves into the practical aspects of clinical trial management, encompassing site selection, regulatory submissions, monitoring, safety reporting, data management, and trial completion. This chapter provides a comprehensive analysis of the regulatory processes involved in clinical trials and their interaction with IPR in the context of vaccine development. It serves as a valuable resource for researchers, policymakers, and industry professionals seeking a deeper understanding of the complex dynamics surrounding vaccine regulation and intellectual property.<br/

Essential oils for clinical aromatherapy: a comprehensive review

Ethnopharmacological relevanceAromatherapy, a holistic healing practice utilizing the aromatic essences of plant-derived essential oils, has gained significant attention for its therapeutic potential in promoting overall well-being. Use of phytoconstituent based essential oil has played a significant role in the evolving therapeutic avenue of aromatherapy as a complementary system of medicine.Aim of the study: This comprehensive review article aims to explore the usage of essential oils for aromatherapy, shedding light on their diverse applications, scientific evidence, and safety considerations. Furthermore, the growing interest in using essential oils as complementary therapies in conjunction with conventional medicine is explored, underscoring the significance of collaborative healthcare approaches.Materials and methodsLiterature search was performed from databases like PubMed, ScienceDirect, Scopus, and Bentham using keywords like Aromatherapy, Aromatic Plants, Essential oils, Phytotherapy, and complementary medicine. The keywords were used to identify literature with therapeutic and mechanistic details of herbal agents with desired action.ResultsThe integration of traditional knowledge with modern scientific research has led to a renewed interest in essential oils as valuable tools in contemporary healthcare. Various extraction methods used to obtain essential oils are presented, emphasizing their impact on the oil's chemical composition and therapeutic properties. Additionally, the article scrutinizes the factors influencing the quality and purity of essential oils, elucidating the significance of standardization and certification for safe usage. A comprehensive assessment of the therapeutic effects of essential oils is provided, encompassing their potential as antimicrobial, analgesic, anxiolytic, and anti-inflammatory agents, among others. Clinical trials and preclinical studies are discussed to consolidate the existing evidence on their efficacy in treating diverse health conditions, both physical and psychological. Safety considerations are of paramount importance when employing essential oils, and this review addresses potential adverse effects, contraindications, and best practices to ensure responsible usage.ConclusionsThis comprehensive review provides valuable insights into the exploration of essential oils for aromatherapy, emphasizing their potential as natural and potent remedies for a wide range of ailments. By amalgamating traditional wisdom and modern research, this article aims to encourage further investigation into the therapeutic benefits of essential oils while advocating for their responsible and evidence-based incorporation into healthcare practices.<br/

Nanoengineered chitosan functionalized titanium dioxide biohybrids for bacterial infections and cancer therapy

Abstract Nanoengineered chitosan functionalized titanium dioxide biohybrids (CTiO2@NPs) were prepared with Amomum subulatum Roxb extract via one-pot green method and assessed by UV–Vis spectroscopy, XRD, SEM and EDAX analyses. As revealed by XRD pattern, the nanohybrids exhibits a rutile TiO2 crystallites around 45 nm in size. The emergence of the Ti–O–Ti bond is identified by observing a peak between 400 and 800 cm−1. A wide bandgap (4.8 eV) has been observed in CTiO2@NPs, due to the quantum confinement effects and the oxygen vacancies reveal the intriguing potential of developed nanohybrids for various applications. Surface flaws were identified by observing an emission band at 382, 437, 482, 517, and 556 nm. They also exhibit better antibacterial performances using well diffusion method against Staphylococcus aureus, Bacillus substilis, Klebsiella pneumonia, and Escherichia coli. CTiO2@NPs were discovered to have free radical scavenging activity on DPPH analysis and exhibit IC50 value as 95.80 μg/mL and standard (Vitamin C) IC50 is 87.62 μg/mL. CTiO2@NPs exhibited better anticancer properties against the osteosarcoma (MG-63) cell line. All these findings suggest that there is a forum for further useful therapeutic applications. Therefore, we claim that nano-engineered carbohydrated TiO2 phytohybrid is a promising solution for bacterial infections and bone cancer

Addressing the resurgence of global monkeypox (Mpox) through advanced drug delivery platforms

Monkeypox (Mpox) is a transmissible infection induced by the Monkeypox virus (a double-stranded DNA virus), recognised under the family orthopoxvirus genus. Monkeypox, like endemic diseases, is a substantial concern worldwide; thus, comprehending the pathogenesis and mutagenesis of amino acids is indispensable to combat the infection. According to the World Health Organization's report, about 89 thousand cases with 160 mortalities have been reported from 114 countries worldwide. The conventional orthopoxvirus vaccines developed on live attenuated viruses exempted any clinical validation from combating monkeypox due to inadequate immunogenicity, toxicity, instability, and multiple doses. Therefore, novel drug delivery systems come into the conception with high biological and mechanical characteristics to address the resurgence of Global Monkeypox. The edges of metallic biomaterials, novel molecules, and vaccine development in targeted therapy increase the modulation of the immune response and blockage of host-virus interaction, with enhanced stability for the antigens. Thus, this review strives to comprehend the viral cell pathogenesis concerning amino acid mutagenesis and current epidemiological standards of the Monkeypox disease across the globe. Furthermore, the review also recapitulates the various clinical challenges, current therapies, and progressive nanomedicine utilisation in the Monkeypox outbreak reinforced by various clinical trial reports. The contemporary challenges of novel drug delivery systems in Monkeypox treatment cannot be overlooked, and thus, authors have outlined the future strategies to develop successful nanomedicine to combat monkeypox. Future pandemics are inevitable but can be satisfactorily handled if we comprehend the crises, innovate, and develop cutting-edge technologies, especially by delving into frontiers like nanotechnology